Clinical Trial Update: Bacillus Velezensis DSM 33864 for Reduction of the Risk of Recurrent Clostridioides Difficile Infections [NA]

View source ↗

Summary

The clinical trial evaluating Bacillus velezensis DSM 33864 to reduce recurrence of Clostridioides difficile infection has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clostridioides Difficile Infection

Drugs mentioned

• Bacillus velezensis DSM 33864

Snippet

Sponsor: Novozymes A/S | Conditions: Clostridium Difficile Infection Recurrence | NA | Status: WITHDRAWN